Show simple item record

dc.contributor.authorPectasides, Dimitriosen
dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorAravantinos, Gerasimosen
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorEfstathiou, E.en
dc.contributor.authorFarmakis, D.en
dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorEconomopoulos, T.en
dc.contributor.authorDimopoulos, M. A.en
dc.creatorPectasides, Dimitriosen
dc.creatorFountzilas, Georgeen
dc.creatorAravantinos, Gerasimosen
dc.creatorKalofonos, H. P.en
dc.creatorEfstathiou, E.en
dc.creatorFarmakis, D.en
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorPavlidis, Nicholasen
dc.creatorEconomopoulos, T.en
dc.creatorDimopoulos, M. A.en
dc.date.accessioned2018-06-22T09:54:23Z
dc.date.available2018-06-22T09:54:23Z
dc.date.issued2006
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42332
dc.description.abstractPurpose.: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stage III and IV OCCC and serous EOC (sEOC). Patients and methods.: A retrospective analysis was performed in patients with advanced stage of OCCC treated with first-line platinum-based chemotherapy in the context of several study protocols of the Hellenic Cooperative Oncology Group (HeCOG) between 1/2/1987 and 31/10/2003. The outcome was compared to that of patients with sEOC treated according to the same protocols during the same study period. Results.: One hundred and five patients (35 stage III and IV OCCC, 70 stage III and IV sEOC) treated with platinum-based chemotherapy were analyzed. The overall response rate for OCCC was 45% (complete response 25%) (95% CI, 23.1% to 68.5%) and 81% (complete response 46%) (95% CI, 67.4% to 91.1%) for sEOC. The overall response rate was significantly higher for sEOC (P = 0.008). In the subgroup of stage III patients, the rate of complete responders was higher among sEOC patients (P = 0.023). After a median follow-up of 61.1 months, median survival and time to tumor progression were not significantly different between the two groups (25.1 months [95% CI 11.7 to 38.5 months] versus 49.1 months [95% CI 36.5 to 61.6 months], P = 0.141, 12.0 months [95% CI 6.5 to 17.3 months] versus 18.0 months [95% CI 14.7 to 21.6 months], P = 0.384, respectively). Conclusion.: Patients with OCCC have significantly lower response to platinum-based first-line chemotherapy compared to patients with sEOC. This low response to platinum-based chemotherapy was not translated in significantly shorter survival. The current study outcomes are provocative and suggest that a new strategy for chemotherapy in OCCC should be adopted, possibly one that focuses on new agents without cross-resistance to platinum agents. © 2006 Elsevier Inc. All rights reserved.en
dc.language.isoengen
dc.sourceGynecologic oncologyen
dc.subjectArticleen
dc.subjectCancer chemotherapyen
dc.subjectHumanen
dc.subjectAdenocarcinomaen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectCancer patienten
dc.subjectFemaleen
dc.subjectMajor clinical studyen
dc.subjectMiddle ageden
dc.subjectAdvanced canceren
dc.subjectCancer growthen
dc.subjectCancer survivalen
dc.subjectFollow upen
dc.subjectNeoplasm stagingen
dc.subjectOvarian neoplasmsen
dc.subjectOvary canceren
dc.subjectPriority journalen
dc.subjectRetrospective studiesen
dc.subjectRetrospective studyen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectCisplatinen
dc.subjectPlatinumen
dc.subjectCancer stagingen
dc.subjectSurvival rateen
dc.subjectOverall survivalen
dc.subjectOutcome assessmenten
dc.subjectSurvivalen
dc.subjectCarboplatinen
dc.subjectSurvival timeen
dc.subjectTherapy effecten
dc.subjectTreatment responseen
dc.subjectPaclitaxelen
dc.subjectCancer regressionen
dc.subjectCombined modality therapyen
dc.subjectComparative studyen
dc.subjectClinical protocolen
dc.subjectEpirubicinen
dc.subjectDoxorubicinen
dc.subjectCyclophosphamideen
dc.subjectClear cellen
dc.subjectClear cell carcinomaen
dc.subjectClear-cell epithelial ovarian canceren
dc.subjectCystadenocarcinomaen
dc.subjectPlatinum-based chemotherapyen
dc.subjectResponseen
dc.subjectSerousen
dc.titleAdvanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experienceen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ygyno.2005.12.038
dc.description.volume102
dc.description.issue2
dc.description.startingpage285
dc.description.endingpage291
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidAravantinos, Gerasimos [0000-0002-2106-1713]
dc.contributor.orcidKalofonos, H. P. [0000-0002-3286-778X]
dc.gnosis.orcid0000-0002-2195-9961
dc.gnosis.orcid0000-0002-2106-1713
dc.gnosis.orcid0000-0002-3286-778X


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record